

**Amendments to the Specification**

Please replace paragraph [0001] with the following amended paragraph:

[0001] This application claims the benefit of priority under 35 U.S.C. §119(e) from U.S. provisional application nos. 60/429,558, filed November 29, 2002, and 60/496,677, filed August 21, 2003, and claims the benefit of priority under 35 U.S.C. §119(a-d) to Japanese patent application no. 142759, filed May 20, 2003, the entire contents of which are incorporated herein by reference.

Please replace paragraph [0061] with the following amended paragraph:

[0061] Zhang et al. (2002) reported that brain damage was induced by reperfusion 30 minutes after the occlusion of the middle cerebral artery (MCA) and was evaluated 24 hours after the reperfusion. Pranlukast (0.003 mg/kg - 1.0 mg/kg) administered intraperitoneally 30 minutes before MCA and 2 hours after reperfusion inhibited the death of brain cells. However, Zhang et al. did not study blood concentrations. Indeed, no blood concentration of pranlukast would be found at 24 hours after the reperfusion at the dose levels (~~0.03 mg/kg~~ 0.003 mg/kg - 1.0 mg/kg) used by Zhang et al.